Experienced in Fragile X Syndrome

Orit Hamiel-Pinhas

4 Bar Ilan Street, 
Ra'anana, M, IL 
Experienced in Fragile X Syndrome
4 Bar Ilan Street, 
Ra'anana, M, IL 
OverviewLocationsClinical Research

Overview

Orit Hamiel-Pinhas practices in Ra'anana, Israel. Ms. Hamiel-Pinhas is rated as an Experienced expert by MediFind in the treatment of Fragile X Syndrome. Her top areas of expertise are Type 1 Diabetes (T1D), Obesity, Obesity in Children, and Diabetic Ketoacidosis.

Her clinical research consists of co-authoring 156 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Fragile X Syndrome.

Gender
Female

Locations

4 Bar Ilan Street, Ra'anana, M, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both
Enrollment Status: Completed
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Enrollment Status: Completed
Publish Date: August 18, 2023
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Enrollment Status: Completed
Publish Date: November 15, 2022
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
View 3 Less Clinical Trials

156 Total Publications

Adolescent Body Mass Index, Weight Trajectories to Adulthood, and Osteoporosis Risk.
Adolescent Body Mass Index, Weight Trajectories to Adulthood, and Osteoporosis Risk.
Journal: JAMA network open
Published: August 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hamiel-Pinhas's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile